8-K: UroGen Pharma Reports Positive Q1 2025 Results and Anticipates UGN-102 FDA Decision

UroGen Pharma announces Q1 2025 financial results with JELMYTO sales growth and prepares for potential FDA approval and commercial launch of UGN-102 in June 2025.

Summary

• UroGen Pharma reported its financial results for the first quarter of 2025.
• JELMYTO net product sales reached $20.3 million, an 8% increase compared to Q1 2024, driven by a 12% growth in underlying demand.
• The company's New Drug Application (NDA) for UGN-102 is under FDA review, with a PDUFA target action date of June 13, 2025.
• An Oncologic Drugs Advisory Committee (ODAC) meeting is scheduled for May 21, 2025, to discuss the UGN-102 NDA.
• Cash, cash equivalents, and marketable securities totaled $200.4 million as of March 31, 2025.
• Full-year 2025 JELMYTO revenue guidance remains unchanged at $94 to $98 million.
• Full-year 2025 operating expenses are expected to be in the range of $215 to $225 million.
• Enrollment is complete in the Phase 1 clinical study of UGN-301, and enrollment is ongoing in the Phase 3 UTOPIA clinical trial of UGN-103, expected to be completed by mid-2025.
• UroGen plans to initiate a Phase 3 trial to explore the safety and efficacy of UGN-104 by mid-2025.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong JELMYTO sales, progress towards UGN-102 approval, and a healthy cash position. However, increased expenses and a net loss temper the overall sentiment.

Positives

• JELMYTO sales are growing, with an 8% increase in Q1 2025 compared to Q1 2024.
• Underlying demand for JELMYTO is strong, with a 12% year-over-year increase.
• UGN-102 is nearing potential FDA approval, with a PDUFA target action date in June 2025.
• UroGen has a strong cash position of $200.4 million as of March 31, 2025.
• The company is advancing its pipeline with ongoing clinical trials for UGN-103 and plans to initiate a trial for UGN-104.
• Updated 18-month Duration of Response (DOR) data from the Phase 3 ENVISION trial evaluating UGN-102 in patients with recurrent LG-IR-NMIBC were featured in a podium presentation by Dr. Sandip Prasad at the American Urological Association (AUA) 2025 Annual Meeting on April 26 in Las Vegas.

Negatives

• UroGen reported a net loss of $43.8 million in Q1 2025, compared to a net loss of $32.3 million in Q1 2024.
• R&D expenses increased to $19.9 million in Q1 2025, driven by the acquisition of UGN-501 and higher manufacturing costs.
• SG&A expenses increased to $35.0 million in Q1 2025, primarily due to UGN-102 commercial preparation activities.

Risks

• The FDA may not approve UGN-102, or the approval may be delayed.
• The ODAC meeting could result in an adverse or split recommendation for UGN-102.
• Commercialization of UGN-102 could face unforeseen challenges.
• Competition in the uro-oncology market could impact UroGen's success.
• Clinical trials for UGN-103 and UGN-104 may not be successful.
• UroGen may need additional capital in the future.

Future Outlook

UroGen anticipates potential FDA approval of UGN-102 in June 2025 and expects to launch the product immediately following approval. The company maintains its full-year 2025 JELMYTO revenue guidance and operating expense guidance.

Management Comments

• Liz Barrett, President and Chief Executive Officer of UroGen, stated that the company is entering a pivotal and exciting period as they approach the anticipated FDA approval of UGN-102.
• Ms. Barrett believes this milestone has the potential to mark the first major advancement in treatment for this patient population in decades.
• Ms. Barrett sees a great opportunity to advance patient care and deliver value for shareholders.

Industry Context

UroGen is focused on developing and commercializing innovative solutions for urothelial and specialty cancers. The potential approval of UGN-102 could provide a new treatment option for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, addressing a significant unmet need in the market. The company's focus on local therapy using its RTGel technology aligns with the trend towards less invasive cancer treatments.

Comparison to Industry Standards

• JELMYTO's performance can be compared to other intravesical therapies for urothelial cancer, such as Bacillus Calmette-Guérin (BCG).
• The median DOR of 47.8 months for JELMYTO in the Phase 3 trial is a key metric to compare against other treatments.
• The 68% recurrence-free survival rate at three years for JELMYTO is also an important benchmark.
• UroGen's pipeline, including UGN-102, UGN-103, and UGN-104, can be compared to the pipelines of other companies in the uro-oncology space, such as CG Oncology and BioCryst Pharmaceuticals.
• The potential $5 billion total addressable market for UGN-102 is a significant opportunity compared to the market sizes for other urothelial cancer treatments.

Stakeholder Impact

• Shareholders may benefit from potential UGN-102 approval and commercial success.
• Patients with urothelial cancer may have access to new treatment options.
• Employees are involved in the development and commercialization of innovative therapies.

Next Steps

• UroGen awaits the ODAC meeting on May 21, 2025, to discuss the UGN-102 NDA.
• The company anticipates a potential FDA decision on UGN-102 by June 13, 2025.
• UroGen plans to launch UGN-102 immediately following potential FDA approval.
• The company will continue to enroll patients in the Phase 3 UTOPIA clinical trial of UGN-103.
• UroGen plans to initiate a Phase 3 trial to explore the safety and efficacy of UGN-104 by mid-2025.

Key Dates

Keywords

UGN-102, JELMYTO, UroGen Pharma, Bladder Cancer, LG-UTUC, NMIBC, Financial Results, Oncology, Pharmaceuticals